The Economics of Preventive Screening: $1.50 vs the Cost of a Crisis

Health systems everywhere say they value prevention. Then they spend almost all their money on crises. The gap between the rhetoric and the budget is not hypocrisy exactly — it is that the crisis is loud and immediate while prevention is quiet and deferred. But the economics, when you actually lay them out, are not close.

The two prices

On one side, a painless multi-parameter screen at our centre or a community camp costs the person somewhere around $1 to $1.50 — about the price of a bus ride. The device that performs it costs under $7 to build and can screen hundreds of people. The cost per person of finding out where you stand on anaemia, oxygen, blood-sugar risk, and heart rhythm is, frankly, trivial.

On the other side is what a late-caught problem costs. Severe anaemia in late pregnancy that needs a transfusion and a complicated delivery. A stroke from undetected atrial fibrillation, with the long, expensive aftermath of disability. Diabetes found only once it has damaged kidneys or eyes. These are not just medically worse outcomes. They are vastly more expensive ones — for the family who usually pays out of pocket, and for the health system that absorbs the complex care.

The comparison is between a dollar and a catastrophe.

Why the cheap option keeps losing

If prevention is so obviously cheaper, why does it lose? A few reasons. The crisis has a face and a deadline; the prevention does not. The cost of not screening is invisible until it arrives, so it does not feel like a cost at all. And the savings from prevention are diffuse — spread across many people, most of whom will never know which crisis they avoided. It is hard to budget for a disaster that, if you succeed, simply never happens.

That is a psychological and political problem more than an economic one. The numbers themselves are not ambiguous.

What makes the maths work in our setting

The reason the economics are so favourable here specifically comes down to the design choices we have written about throughout. A device that costs under $7 and runs off a phone with no battery means the screening infrastructure is cheap to deploy and cheap to maintain. Consolidating several checks into one painless test means you are not paying for four separate devices and four separate visits. Training local operators means you are not flying in expensive specialists. Each choice drives the cost per screen down toward the price of a bus ride.

At that price, screening a whole community becomes affordable rather than aspirational. And every serious problem caught early — every transfusion, stroke, or diabetic complication prevented — is a large cost avoided in exchange for a tiny one spent.

The honest framing

We are not claiming a screen is free or that prevention eliminates crises. Some problems will still progress, and a screen is a first look, not a cure. But the basic trade is as clear as health economics gets: pay a little, near home, painlessly, to find problems while they are still cheap to fix — or pay enormously, later, when they are not. For families who can least afford the catastrophe, getting the cheap option to their doorstep is not a nicety. It is the difference between a manageable expense and a ruinous one.